(Reuters) -The impact of U.S. President Donald Trump’s plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, according to an analysis by brokerage Morningstar.

The report said the near term risk from the push to slash prescription drug prices to match those paid overseas would be “exceedingly low” as it could harm patient access to drugs.

In July, Trump had called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs.

The report looked at ten major pharmaceutical firms in the U.S. and Europe – AstraZeneca , Novartis, Sanofi, GSK, Novo Nordisk, AbbV

See Full Page